Your browser does not fully support modern features. Please upgrade for a smoother experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 handwiki Dean Liu -- 5937 2022-10-25 01:44:23

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
HandWiki. Transgender Hormone Therapy (Female-to-Male). Encyclopedia. Available online: https://encyclopedia.pub/entry/31136 (accessed on 10 September 2026).
HandWiki. Transgender Hormone Therapy (Female-to-Male). Encyclopedia. Available at: https://encyclopedia.pub/entry/31136. Accessed September 10, 2026.
HandWiki. "Transgender Hormone Therapy (Female-to-Male)" Encyclopedia, https://encyclopedia.pub/entry/31136 (accessed September 10, 2026).
HandWiki. (2022, October 25). Transgender Hormone Therapy (Female-to-Male). In Encyclopedia. https://encyclopedia.pub/entry/31136
HandWiki. "Transgender Hormone Therapy (Female-to-Male)." Encyclopedia. Web. 25 October, 2022.
Transgender Hormone Therapy (Female-to-Male)
Edit
The content is sourced from: https://handwiki.org/wiki/Medicine:Transgender_hormone_therapy_(female-to-male)

Transgender hormone therapy of the masculinizing type, also known as transmasculine hormone therapy, or female-to-male (or FTM) hormone therapy, is a form of hormone therapy and gender affirming therapy which is used to change the secondary sexual characteristics of transgender people from feminine or androgynous to masculine. It is a type of transgender hormone therapy (another being male-to-female), and is predominantly used to treat transgender men and other transmasculine individuals. Some intersex people also receive this form of therapy, either starting in childhood to confirm the assigned sex or later if the assignment proves to be incorrect. The purpose of this form of therapy is to cause the development of the secondary sex characteristics of the desired sex, such as voice deepening and a masculine pattern of hair, fat, and muscle distribution. It cannot undo many of the changes produced by naturally occurring puberty, which may necessitate surgery and other treatments to reverse. The medications used for FTM therapy include, mainly, androgens (namely testosterone) and GnRH analogues. While the therapy cannot undo the effects of a person's first puberty, developing secondary sex characteristics associated with a different sex can relieve some or all of the distress and discomfort associated with gender dysphoria, and can help the person to "pass" or be seen as the gender they identify with. Introducing exogenous hormones into the body impacts it at every level and many patients report changes in energy levels, mood, appetite, etc. The goal of the therapy, and indeed all somatic treatments, is to provide patients with a more satisfying body that is more congruent with their gender identity.

transmasculine masculinizing transgender men

References

  1. Hembree, W.C. (September 2009). "Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline". Journal of Clinical Endocrinology & Metabolism. p. 18. http://www.endocrine.org/~/media/endosociety/Files/Publications/Clinical%20Practice%20Guidelines/Endocrine-Treatment-of-Transsexual-Persons.pdf. Retrieved March 13, 2014. 
  2. Nota, N. M.; Wiepjes, C. M.; de Blok CJM; Gooren LJG; Kreukels BPC; Den Heijer, M. (2019). "Nota NM, Wiepjes CM, de Blok, C. J. M., Gooren LJG, Kreukels BPC, den Heijer M. "Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy." Circulation (2019).". Circulation 139 (11): 1461–1462. doi:10.1161/CIRCULATIONAHA.118.038584. PMID 30776252.  https://dx.doi.org/10.1161%2FCIRCULATIONAHA.118.038584
  3. Alzahrani, T.; Nguyen, T.; Ryan, A.; Dwairy, A.; McCaffrey, J.; Yunus, R.; Forgione, J.; Krepp, J. et al. (2019). "Alzahrani T, Nguyen T, Ryan A, et al. "Cardiovascular disease risk factors and myocardial infarction in the transgender population." Circ Cardiovasc Qual Outcomes (2019).". Circ Cardiovasc Qual Outcomes 12 (4): e005597. doi:10.1161/CIRCOUTCOMES.119.005597. PMID 30950651.  https://dx.doi.org/10.1161%2FCIRCOUTCOMES.119.005597
  4. "Aveed (testosterone undecanoate) FDA Approval History". https://www.drugs.com/history/aveed.html. Retrieved 9 May 2019. 
  5. "FDA Approves Aveed Testosterone Jab, with Restrictions". March 7, 2014. http://www.medscape.com/viewarticle/821632. Retrieved December 13, 2016. 
  6. Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 63–. ISBN 978-3-88763-075-1. https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA63. 
  7. Thomas E. Hyde; Marianne S. Gengenbach (2007). Conservative Management of Sports Injuries. Jones & Bartlett Learning. pp. 1100–. ISBN 978-0-7637-3252-3. https://books.google.com/books?id=uzPwfNYyjjUC&pg=PA1100. 
  8. "Dermatologic care of the transgender patient". Int J Womens Dermatol 3 (1): 65–67. 2017. doi:10.1016/j.ijwd.2016.11.007. PMID 28492057. "In addition, oral finasteride may block the development of wanted secondary physical features, including voice change, body hair and composition, and clitoromegaly. Therefore, it is important to ensure that all desired changes are complete before the initiation of treatment with finasteride, which is frequently after 2 years of testosterone use.".  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5418958
  9. "Standards of Care, Version 7". Archived from the original on January 28, 2014. https://web.archive.org/web/20140128104021/http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1351&pk_association_webpage=3926. Retrieved December 13, 2016. 
  10. Grimstad FW, Fowler KG, New EP, Ferrando CA, Pollard RR, Chapman G, Gomez-Lobo V, Gray M (2019). "Uterine pathology in transmasculine persons on testosterone: a retrospective multicenter case series.". The American Journal of Obstetrics and Gynecology 220 (3): 257.E1-E7. doi:10.1016/j.ajog.2018.12.021. PMID 30579875. https://www.ajog.org/article/S0002-9378(18)32231-2/fulltext. 
  11. Krempasky C, Harris M, Abern L, Grimstad F (2020). "Contraception across the transmasculine spectrum". The American Journal of Obstetrics and Gynecology 222 (2): 134–143. doi:10.1016/j.ajog.2019.07.043. PMID 31394072. https://www.ajog.org/article/S0002-9378(19)30955-X/fulltext. 
  12. Hulshoff, Cohen-Kettenis et al. (July 2006). "Changing your sex changes your brain: influences of testosterone and estrogen on adult human brain structure". European Journal of Endocrinology 155 (suppl_1): 107–114. doi:10.1530/eje.1.02248. ISSN 0804-4643. http://www.eje-online.org/cgi/content/abstract/155/suppl_1/S107. Retrieved 2007-12-12. 
  13. Does Testosterone Treatment Increase Anger Expression in a Population of Transgender Men? Giovanna Motta , Chiara Crespi , Valentina Mineccia , Paolo Riccardo Brustio , Chiara Manieri , Fabio Lanfranco, https://pubmed.ncbi.nlm.nih.gov/29175227/
  14. Goetz, Laura G.; Mamillapalli, Ramanaiah; Sahin, Cagdas; Majidi-Zolbin, Masoumeh; Ge, Guanghao; Mani, Arya; Taylor, Hugh S. (2017). "Addition of Estradiol to Cross-sex Testosterone Therapy Reduces Atherosclerosis Plaque Formation in Female ApoE -/- Mice". Endocrinology 159 (2): 754–762. doi:10.1210/en.2017-00884. PMID 29253190.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5774248
  15. Polderman K (1994). "Induction of insulin resistance by androgens and estrogens". Journal of Clinical Endocrinology & Metabolism 79 (1): 265–71. doi:10.1210/jc.79.1.265.  https://dx.doi.org/10.1210%2Fjc.79.1.265
  16. van Kesteren P (1998). "Long-term follow-up of bone mineral density and bone metabolism in transsexuals treated with cross-sex hormones". Clin Endocrinol 48 (3): 347–54. doi:10.1046/j.1365-2265.1998.00396.x. https://semanticscholar.org/paper/d4cb44fcad5c66f04fd310c6fca4f9d31194ca5b. 
  17. Goetz, Laura G.; Mamillapalli, Ramanaiah; Devlin, Maureen J.; Robbins, Amy E.; Majidi-Zolbin, Masoumeh; Taylor, Hugh S. (2017-11-01). "Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture". American Journal of Physiology. Endocrinology and Metabolism 313 (5): E540–E551. doi:10.1152/ajpendo.00161.2017. ISSN 1522-1555. PMID 28765273.  http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5792142
  18. Gianna E. Israel; Donald E. Tarver; Joy Diane Shaffer (26 April 2001). Transgender Care: Recommended Guidelines, Practical Information, and Personal Accounts. Temple University Press. p. 69. ISBN 978-1-56639-852-7. https://books.google.com/books?id=IlPX6E5glDEC&pg=PA69. Retrieved 18 July 2012. 
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Others
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
HandWiki
View Times: 2.0K
Entry Collection: HandWiki
Revision: 1 time (View History)
Update Date: 26 Oct 2022
Table of Contents
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    There is no comment~
    ${ textCharacter }/${ maxCharacter }
    Submit
    Cancel
    ${ selectedItem.replyTextCharacter }/${ selectedItem.replyMaxCharacter }
    Submit
    Cancel
    Confirm
    Are you sure to Delete?
    Yes No
    Academic Video Service
    Feedback